newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight

ISELIN, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indicat